Drugs in the Pipeline

RRx-001 is an investigational small molecule inflammasome NLRP3 inhibitor and Nrf2 upregulator with antioxidant and anti-inflammatory properties.

Osemitamab is a high affinity, humanized antibody-dependent cellular cytotoxicity (ADCC)-enhanced anti-Claudin18.2 monoclonal antibody.

If approved, Opill would be the first daily oral contraceptive pill available without a prescription.

Lumateperone 42mg given once daily met the primary endpoint in the study.

Zagociguat is a CNS-penetrant sGC stimulator.

The letter states that the application cannot be approved in its present form.

Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.

Results showed that 20.3% of patients treated with risankizumab achieved clinical remission at week 12 compared with 6.2% of patients who received placebo.

Treatment with dupilumab led to a significant 30% reduction in moderate or severe acute COPD exacerbations.

A multiple ascending dose study of a second generation formulation of ganaxolone is expected to begin in the second quarter of 2023.